Multicentre experience of home omalizumab treatment for chronic spontaneous urticaria.
Eur J Hosp Pharm
; 27(6): 367-368, 2020 11.
Article
em En
| MEDLINE
| ID: mdl-33097621
ABSTRACT
INTRODUCTION:
Due to perceived risk of anaphylaxis, home treatment with omalizumab has been limited. Within the UK, most centres administer omalizumab in a hospital setting. However, the reported prevalence of anaphylaxis is low and in December 2018 home treatment became licensed. A home treatment pathway was previously reported by one UK centre, and this update describes three UK centres' experience of home omalizumab treatment.METHODS:
The medical records of omalizumab patients were retrospectively reviewed.RESULTS:
A total of 137 adult patients have received home omalizumab treatment; home treatment duration 0-44 months. There was no increase in adverse effects seen in patients treated at home. There were no reported adherence issues and no reduction in efficacy. Patients report they prefer home treatment due to increased flexibility and reduced impact on daily life/work.CONCLUSION:
Home treatment with omalizumab is a safe and effective alternative to hospital administration.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antialérgicos
/
Omalizumab
/
Urticária Crônica
/
Serviços de Assistência Domiciliar
Tipo de estudo:
Diagnostic_studies
/
Observational_studies
/
Risk_factors_studies
Limite:
Adult
/
Female
/
Humans
/
Male
País/Região como assunto:
Europa
Idioma:
En
Revista:
Eur J Hosp Pharm
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Reino Unido